Every article, report, and earnings note where IONS appears.
4 articles
Ionis Pharmaceuticals, Inc. (IONS) drops sharply after a Phase 3 ATTR-CM trial for eplontersen missed its primary endpoint, pressuring the stock on heavy volume. The setback trims a key growth opportunity, even as the company continues to show solid commercial execution and a strong earnings track record.
Ionis got hit as if the Wainua trial miss broke the whole equity story, and that looks too simplistic. The bigger near-term driver is now TRYNGOLZA's expanded launch, with commercial revenue already up 42% and management raising its olezarsen peak-sales view above $3 billion.
Ionis is evolving into a multi-product commercial RNA medicines company, with TRYNGOLZA and DAWNZERA driving real revenue growth and a larger market opportunity now open for TRYNGOLZA.
Ionis Pharmaceuticals, Inc. (IONS) slumps after hours after a Phase 3 CARDIO-TTRansform trial miss for eplontersen, also known as WAINUA. The setback dents a key expansion story in ATTR-CM and raises questions about future royalty growth, even as the company remains commercially diversified.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate IONS Report